retatrutide phase 2 results obesity nejm 2023 Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released trial demonstrating 25% weight loss in half of people with #obesity. This amount of weight loss has not been accomplished Retatrutide vs Tirzepatide: Best Triple

This study, which focused on adults with Type 2 diabetes, showed that retatrutide achieved an average A1C reduction of up to 2.0% and significant body weight loss in just 40 weeks

Understanding when lifestyle modifications alone may be insufficient helps ensure appropriate and timely medical intervention

Let us help you rediscover confidence in your body and feel renewed from the inside out

How effective is retatrutide for subcutaneous fat loss

In practice, because the FDA governs drug approvals in the United States and most Western countries follow similar regulatory frameworks, the 27 threshold remains the functional standard for clinical practice

However, clinical trials such as STEP-4 demonstrate that weight regain typically occurs after discontinuation of therapy